Antiviral Treatment Reduces Risk of Development of Lung Cancer and Non–Hodgkin Lymphoma in Patients with Chronic Hepatitis C
Our findings support the importance of timely initiation antiviral therapy in patients with chronic HCV.
Authors
- Sheri Trudeau (ORCID: https://orcid.org/0000-0003-1280-0833)
- Mark A. Schmidt (ORCID: https://orcid.org/0000-0002-7440-7183)
- Stuart C. Gordon (ORCID: https://orcid.org/0000-0001-8666-3849)
- Loralee B. Rupp (ORCID: https://orcid.org/0000-0002-2048-5100)
- Yihe Goh Daida (ORCID: https://orcid.org/0000-0003-1628-0476)
- Mei Lü (ORCID: https://orcid.org/0000-0002-3313-6428)
- Yueren Zhou (ORCID: https://orcid.org/0000-0002-8222-8644)
- Trueman Wu (ORCID: https://orcid.org/0009-0000-8237-0862)
- Meng Hua Tao (ORCID: https://orcid.org/0000-0001-9944-2105)
Institutions
- Hawaii Department of Health (US)
- Kaiser Permanente (US)
- Henry Ford Health System (US)
- Oregon Health & Science University (US)
- Wayne State University (US)
- Henry Ford Hospital (US)
- Kaiser Permanente Center for Health Research (US)
Publication Details
- Journal
- Cancer Epidemiology Biomarkers & Prevention
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1158/1055-9965.epi-25-0617
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.32